Results 311 to 320 of about 1,417,591 (372)

Medication for opioid use disorder service delivery in carceral facilities: update and summary report. [PDF]

Health Justice
Berk J, South AM, Martin M, James ME, Miller C, Haber L, Rich J.   +6 more
europepmc   +1 more source

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

The Journal of Dermatology, EarlyView.
Yoshihide Asano, Jun Asai, Takayuki Ishii, Yohei Iwata, Masanari Kodera, Chie Miyabe, Akihiko Uchiyama, Youichi Ogawa, Ken Okamura, Mari Kishibe, Yuta Koike, Yorihisa Kotobuki, Noriki Fujimoto, Takuya Miyagi, Yukie Yamaguchi, Ayumi Yoshizaki, Reiko Omori, Takeshi Nakanishi, Hiroshi Fujiwara, Takeo Maekawa, Sei‐ichiro Motegi, Yuichiro Yoshino, Minoru Hasegawa, Manabu Fujimoto, Takao Tachibana, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group)   +27 more
wiley   +1 more source

Efficacy of cannabidiol alone or in combination with Δ‐9‐tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence

Addiction, Volume 120, Issue 5, Page 813-834, May 2025.
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as a potential therapeutic target due to its pharmacological properties and mode of action in the endocannabinoid system.
Bertrand Redonnet, Filiz Eren, Guillaume Avenin, Maria Melchior, Murielle Mary‐Krause   +4 more
wiley   +1 more source

Sonographic features of internal carotid artery in patients with opioid use disorder: Is opium a new risk factor for atherosclerosis of internal carotid artery? [PDF]

J Res Med Sci
Masoumi Z, Najafi MA, Mohammadi AS, Saadatnia M.   +3 more
europepmc   +1 more source

Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019

Addiction, Volume 120, Issue 5, Page 951-961, May 2025.
Abstract Background and Aim Sedative, hypnotic or anxiolytic use disorders (SHA‐UD) are defined by significant impairment or distress caused by recurrent sedative, hypnotic or anxiolytic use. This study aimed to measure trends in the prevalence of SHA‐UD diagnoses in adolescent and young adult US Medicaid enrollees from 2001 to 2019.
Greta Bushnell, Kristen Lloyd, Mark Olfson, Tobias Gerhard, Katherine Keyes, Magdalena Cerdá, Deborah Hasin   +6 more
wiley   +1 more source

Rest-Activity Rhythms, Their Modulators, and Brain-Clinical Correlates in Opioid Use Disorder.

JAMA Netw Open
Zhang R, Manza P, Demiral SB, Tomasi D, Yonga MV, Yan W, Shokri-Kojori E, Schwandt M, Vines L, Sotelo D, Lildharrie C, Lin E, Giddens NT, Wang GJ, Volkow ND.   +14 more
europepmc   +1 more source

A phase I pilot study of a mobile education tool for supporting pregnant women with opioid use disorder. [PDF]

Drug Alcohol Depend Rep
Burduli E, Willoughby JF, Paulsgrove K, Winquist A, McPherson SM, Johnson RK, Jones HE.   +6 more
europepmc   +1 more source

Recovery support services as part of the continuum of care for alcohol or drug use disorders

Addiction, EarlyView.
Abstract Background The definition of ‘recovery’ has evolved beyond merely control of problem substance use to include other aspects of health and wellbeing (known as ‘recovery capital’) which are important to prevent relapse to problematic alcohol or other drug (AOD) use.
Ed Day, Laura Charlotte Pechey, Suzie Roscoe, John F. Kelly   +3 more
wiley   +1 more source

Smartphone App-Based Contingency Management and Opioid Use Disorder Treatment Outcomes.

JAMA Netw Open
Marino EN, Karns-Wright T, Perez MC, Potter JS.   +3 more
europepmc   +1 more source

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention. [PDF]

Int J Neuropsychopharmacol
Tuncturk M, Kushwaha S, Heider RM, Oesterle T, Weinshilboum R, Ho MF.   +5 more
europepmc   +1 more source